29 August 2016 - Neurocrine Biosciences today announced that it has submitted a new drug application to the U.S. FDA for once-daily dosing of valbenazine in treating tardive dyskinesia.
"This is an important milestone in the development of valbenazine for the treatment of tardive dyskinesia, a serious disease for which there is no FDA approved pharmaceutical treatment," said Kevin C. Gorman, President and Chief Executive Officer of Neurocrine Biosciences. "We look forward to working with the FDA in their review of the valbenazine NDA submission to potentially bring this important treatment option to patients and physicians."